产品
编 号：F625695
分子式：C50H47Cl2N3O6
分子量：856.83
分子式：C50H47Cl2N3O6
分子量：856.83
产品类型
规格
价格
是否有货
结构图
CAS No: 1246826-07-2
产品详情
生物活性：
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.
体内研究：
TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice.Animal Model:Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests
Dosage:3 mg/kg
Administration:Intravenous injection (Single dose)
Result:Induced plasma insulin.
体外研究：
TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells.
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.
体内研究：
TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice.Animal Model:Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests
Dosage:3 mg/kg
Administration:Intravenous injection (Single dose)
Result:Induced plasma insulin.
体外研究：
TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备